"Global Oncolytic Virus Therapy Market Overview:
Global Oncolytic Virus Therapy Market is expected to grow at a significant rate during the forecast period 2025-2032, with 2024 as the base year.
Global Oncolytic Virus Therapy Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Oncolytic Virus Therapy involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Oncolytic Virus Therapy Market:
The Oncolytic Virus Therapy Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Oncolytic Virus Therapy Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Oncolytic Virus Therapy Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Oncolytic Virus Therapy market has been segmented into:
Herpes simplex virus
Adenovirus
Vaccinia virus
Reovirus
Measles virus
Others
By Application, Oncolytic Virus Therapy market has been segmented into:
Melanoma
Breast cancer
Head and neck cancer
Bladder Cancer
Prostate Cancer
Lung Cancer
Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Oncolytic Virus Therapy market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Oncolytic Virus Therapy market.
Top Key Players Covered in Oncolytic Virus Therapy market are:
Amgen Inc.
Merck & Co.
Inc.
Oncolytics Biotech Inc.
Circio Holding ASA
Akamis Bio
Vyriad
Inc.
SillaJen Biotherapeutics
Cold Genesys Inc.
Sorrento Therapeutics
Inc.
Takara Bio Inc.
Replimune Group Inc.
Genelux Corporation
Synthetic Biologics
Inc.
Lokon Pharma AB
Elicera Therapeutics
"
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Oncolytic Virus Therapy Market by Type
4.1 Oncolytic Virus Therapy Market Snapshot and Growth Engine
4.2 Oncolytic Virus Therapy Market Overview
4.3 Herpes simplex virus
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Herpes simplex virus: Geographic Segmentation Analysis
4.4 Adenovirus
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Adenovirus: Geographic Segmentation Analysis
4.5 Vaccinia virus
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Vaccinia virus: Geographic Segmentation Analysis
4.6 Reovirus
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Reovirus: Geographic Segmentation Analysis
4.7 Measles virus
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 Measles virus: Geographic Segmentation Analysis
4.8 Others
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.8.3 Key Market Trends, Growth Factors and Opportunities
4.8.4 Others: Geographic Segmentation Analysis
Chapter 5: Oncolytic Virus Therapy Market by Application
5.1 Oncolytic Virus Therapy Market Snapshot and Growth Engine
5.2 Oncolytic Virus Therapy Market Overview
5.3 Melanoma
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Melanoma: Geographic Segmentation Analysis
5.4 Breast cancer
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Breast cancer: Geographic Segmentation Analysis
5.5 Head and neck cancer
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Head and neck cancer: Geographic Segmentation Analysis
5.6 Bladder Cancer
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Bladder Cancer: Geographic Segmentation Analysis
5.7 Prostate Cancer
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Prostate Cancer: Geographic Segmentation Analysis
5.8 Lung Cancer
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.8.3 Key Market Trends, Growth Factors and Opportunities
5.8.4 Lung Cancer: Geographic Segmentation Analysis
5.9 Others
5.9.1 Introduction and Market Overview
5.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.9.3 Key Market Trends, Growth Factors and Opportunities
5.9.4 Others: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Oncolytic Virus Therapy Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 AMGEN INC.
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 MERCK & CO.
6.4 INC.
6.5 ONCOLYTICS BIOTECH INC.
6.6 CIRCIO HOLDING ASA
6.7 AKAMIS BIO
6.8 VYRIAD
6.9 INC.
6.10 SILLAJEN BIOTHERAPEUTICS
6.11 COLD GENESYS INC.
6.12 SORRENTO THERAPEUTICS
6.13 INC.
6.14 TAKARA BIO INC.
6.15 REPLIMUNE GROUP INC.
6.16 GENELUX CORPORATION
6.17 SYNTHETIC BIOLOGICS
6.18 INC.
6.19 LOKON PHARMA AB
6.20 AND ELICERA THERAPEUTICS
Chapter 7: Global Oncolytic Virus Therapy Market By Region
7.1 Overview
7.2. North America Oncolytic Virus Therapy Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 Herpes simplex virus
7.2.4.2 Adenovirus
7.2.4.3 Vaccinia virus
7.2.4.4 Reovirus
7.2.4.5 Measles virus
7.2.4.6 Others
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Melanoma
7.2.5.2 Breast cancer
7.2.5.3 Head and neck cancer
7.2.5.4 Bladder Cancer
7.2.5.5 Prostate Cancer
7.2.5.6 Lung Cancer
7.2.5.7 Others
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Oncolytic Virus Therapy Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 Herpes simplex virus
7.3.4.2 Adenovirus
7.3.4.3 Vaccinia virus
7.3.4.4 Reovirus
7.3.4.5 Measles virus
7.3.4.6 Others
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Melanoma
7.3.5.2 Breast cancer
7.3.5.3 Head and neck cancer
7.3.5.4 Bladder Cancer
7.3.5.5 Prostate Cancer
7.3.5.6 Lung Cancer
7.3.5.7 Others
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe Oncolytic Virus Therapy Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 Herpes simplex virus
7.4.4.2 Adenovirus
7.4.4.3 Vaccinia virus
7.4.4.4 Reovirus
7.4.4.5 Measles virus
7.4.4.6 Others
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Melanoma
7.4.5.2 Breast cancer
7.4.5.3 Head and neck cancer
7.4.5.4 Bladder Cancer
7.4.5.5 Prostate Cancer
7.4.5.6 Lung Cancer
7.4.5.7 Others
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific Oncolytic Virus Therapy Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 Herpes simplex virus
7.5.4.2 Adenovirus
7.5.4.3 Vaccinia virus
7.5.4.4 Reovirus
7.5.4.5 Measles virus
7.5.4.6 Others
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Melanoma
7.5.5.2 Breast cancer
7.5.5.3 Head and neck cancer
7.5.5.4 Bladder Cancer
7.5.5.5 Prostate Cancer
7.5.5.6 Lung Cancer
7.5.5.7 Others
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Oncolytic Virus Therapy Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 Herpes simplex virus
7.6.4.2 Adenovirus
7.6.4.3 Vaccinia virus
7.6.4.4 Reovirus
7.6.4.5 Measles virus
7.6.4.6 Others
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Melanoma
7.6.5.2 Breast cancer
7.6.5.3 Head and neck cancer
7.6.5.4 Bladder Cancer
7.6.5.5 Prostate Cancer
7.6.5.6 Lung Cancer
7.6.5.7 Others
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Oncolytic Virus Therapy Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 Herpes simplex virus
7.7.4.2 Adenovirus
7.7.4.3 Vaccinia virus
7.7.4.4 Reovirus
7.7.4.5 Measles virus
7.7.4.6 Others
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Melanoma
7.7.5.2 Breast cancer
7.7.5.3 Head and neck cancer
7.7.5.4 Bladder Cancer
7.7.5.5 Prostate Cancer
7.7.5.6 Lung Cancer
7.7.5.7 Others
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Oncolytic Virus Therapy Scope:
|
Report Data
|
Oncolytic Virus Therapy Market
|
|
Oncolytic Virus Therapy Market Size in 2025
|
USD XX million
|
|
Oncolytic Virus Therapy CAGR 2025 - 2032
|
XX%
|
|
Oncolytic Virus Therapy Base Year
|
2024
|
|
Oncolytic Virus Therapy Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Amgen Inc., Merck & Co., Inc., Oncolytics Biotech Inc., Circio Holding ASA, Akamis Bio, Vyriad, Inc., SillaJen Biotherapeutics, Cold Genesys Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., Replimune Group Inc., Genelux Corporation, Synthetic Biologics, Inc., Lokon Pharma AB, and Elicera Therapeutics.
|
|
Key Segments
|
By Type
Herpes simplex virus
Adenovirus
Vaccinia virus
Reovirus
Measles virus
Others
By Applications
Melanoma
Breast cancer
Head and neck cancer
Bladder Cancer
Prostate Cancer
Lung Cancer
Others
|
